CPhI Online

- Biopharma News

Catalent secures Trizell cell therapy development and manufacturing contract

8 Feb 2021

The agreement allows the CDMO to "stay on the forefront of emerging indications and cell types"

CDMO Catalent has signed an agreement with German biotech company, Trizell, to support the manufacturing of its Phase I cell therapy for the treatment of micro- and macroangiopathies.

Trizell’s therapeutic is an advanced therapy medicinal product (ATMP) and uses regulatory macrophages (Mregs), a platform technology developed in Germany.

Initial development work will take place at the University Medical Center Schleswig Holstein (UKSH), Department of Anesthesiology and Intensive Care Medicine, the Clinic for Applied Cellular Medicine, and the Department of Cardiovascular Surgery, in collaboration with Catalent.

CGMP (current good manufacturing practice) manufacturing of the cell therapy will take place at Catalent’s 25,000-sq. ft (2,300 m2) facility in Gosselies, Belgium, which provides development and clinical GMP manufacturing services.

Catalent is continuing construction on a dedicated 60,000-sq. ft (5,574 m2) adjacent commercial-scale production and fill-finish facility, which is scheduled to open in 2022.

"Extending into areas such as macrophages, allows us to stay on the forefront of emerging indications and cell types," said Dr Manja Boerman, President, Catalent Cell & Gene Therapy.

Last October, Catalent announced an agreement with Bone Therapeutics to acquire its cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA, including all of its assets located in Gosselies, which includes a purpose-built 41,000-sq. ft (3,800 m2) CGxP development and GMP manufacturing facility next to the existing Catalent facility.

Read More

Related Content